Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill aims to slow advanced cancers in early trial

NCT ID NCT07252661

First seen Jan 07, 2026

Summary

This early-phase study tests an experimental pill, ACC-1898, in 40 adults with advanced solid tumors (like liver, kidney, or stomach cancer) who have no other treatment options. The main goal is to find a safe dose and see how the body handles the drug. Researchers will also check if the drug can slow tumor growth over up to two years of daily treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

gallbladder neoplasm hepatocellular carcinoma melanoma Neoplasm Metastasis renal cell carcinoma Thyroid cancer, medullary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.